Galectin Therapeutics (GALT) Payables (2010 - 2026)
Galectin Therapeutics' quarterly Payables came in at $3.1 million in Q1 2026, down 52.23% year-on-year from $6.5 million in Q1 2025, and down 5.65% quarter-over-quarter from $3.3 million in Q4 2025.
Galectin Therapeutics has reported Payables for 17 years, with the latest figure at $3.1 million in Q1 2026.
- For the quarter ending Q1 2026, Payables fell 52.23% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 million (down 52.23% YoY), and the FY2025 full-year result was $3.3 million, down 42.16% from the prior year.
- Payables for Q1 2026 stood at $3.1 million, down from $3.3 million in the prior quarter.
- The five-year high for Payables was $6.5 million in Q1 2025, with the low at $1.9 million in Q1 2022.
- Average Payables over 5 years is $3.8 million, with a median of $3.3 million recorded in 2025.
- Year-over-year, Payables soared 398.95% in 2022 and tumbled 52.23% in 2026.
- Tracing GALT's Payables over 5 years: stood at $4.0 million in 2022, then jumped by 64.24% to $6.5 million in 2023, then declined by 11.93% to $5.7 million in 2024, then plunged by 42.16% to $3.3 million in 2025, then slipped by 5.65% to $3.1 million in 2026.
- The last three Payables figures came in at $3.1 million (Q1 2026), $3.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.12 Mn |
| Dec 31, 2025 | 3.31 Mn |
| Sep 30, 2025 | 5.39 Mn |
| Jun 30, 2025 | 5.93 Mn |
| Mar 31, 2025 | 6.53 Mn |
| Dec 31, 2024 | 5.72 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 3.76 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 6.49 Mn |
| Sep 30, 2023 | 2.68 Mn |
| Jun 30, 2023 | 2.04 Mn |
| Mar 31, 2023 | 2.55 Mn |
| Dec 31, 2022 | 3.95 Mn |
| Sep 30, 2022 | 2.35 Mn |
| Jun 30, 2022 | 3.03 Mn |
| Mar 31, 2022 | 1.91 Mn |
| Dec 31, 2021 | 1.87 Mn |
| Sep 30, 2021 | 1.92 Mn |
| Jun 30, 2021 | 989,000.00 |
| Mar 31, 2021 | 382,000.00 |
| Dec 31, 2020 | 1.36 Mn |
| Sep 30, 2020 | 691,000.00 |
| Jun 30, 2020 | 272,000.00 |
| Mar 31, 2020 | 660,000.00 |
| Dec 31, 2019 | 1.73 Mn |
| Sep 30, 2019 | 354,000.00 |
| Jun 30, 2019 | 462,000.00 |
| Mar 31, 2019 | 448,000.00 |
| Dec 31, 2018 | 596,000.00 |
| Sep 30, 2018 | 171,000.00 |
| Jun 30, 2018 | 287,000.00 |
| Mar 31, 2018 | 1.15 Mn |
| Dec 31, 2017 | 676,000.00 |
| Sep 30, 2017 | 166,000.00 |
| Jun 30, 2017 | 467,000.00 |
| Mar 31, 2017 | 1.35 Mn |
| Dec 31, 2016 | 978,000.00 |
| Sep 30, 2016 | 652,000.00 |
| Jun 30, 2016 | 1.00 Mn |
| Mar 31, 2016 | 1.31 Mn |
| Dec 31, 2015 | 515,000.00 |
| Sep 30, 2015 | 929,000.00 |
| Jun 30, 2015 | 843,000.00 |
| Mar 31, 2015 | 922,000.00 |
| Dec 31, 2014 | 974,000.00 |
| Sep 30, 2014 | 838,000.00 |
| Jun 30, 2014 | 734,000.00 |
| Mar 31, 2014 | 486,000.00 |
| Dec 31, 2013 | 835,000.00 |
| Sep 30, 2013 | 377,000.00 |
| Jun 30, 2013 | 364,000.00 |
| Mar 31, 2013 | 316,000.00 |
| Dec 31, 2012 | 477,000.00 |
| Sep 30, 2012 | 256,000.00 |
| Jun 30, 2012 | 326,000.00 |
| Mar 31, 2012 | 669,000.00 |
| Dec 31, 2011 | 464,000.00 |
| Sep 30, 2011 | 198,000.00 |
| Jun 30, 2011 | 210,000.00 |
| Dec 31, 2010 | 173,000.00 |